Pruritus Reduction with Systemic Anti-lymphoma Treatments in Patients with Cutaneous T Cell Lymphoma: A Narrative Review - Wikidata - wikimedia - TriplyDB

Pruritus Reduction with Systemic Anti-lymphoma Treatments in Patients with Cutaneous T Cell Lymphoma: A Narrative Review

Pruritus Reduction with Systemic Anti-lymphoma Treatments in Patients with Cutaneous T Cell Lymphoma: A Narrative Review

http://www.wikidata.org/entity/Q28075343

about

Erratum to: Pruritus Reduction with Systemic Anti-lymphoma Treatments in Patients with Cutaneous T Cell Lymphoma: A Narrative Review.

P921

Q42364286-6C2A09F3-B699-4F05-A05E-A75014332982

P921

Pruritus Reduction with Systemic Anti-lymphoma Treatments in Patients with Cutaneous T Cell Lymphoma: A Narrative Review

http://www.wikidata.org/entity/Q28075343

description

2016 nî lūn-bûn

@nan

2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Pruritus Reduction with System ...... l Lymphoma: A Narrative Review

@ast

Pruritus Reduction with System ...... l Lymphoma: A Narrative Review

@en

Pruritus Reduction with System ...... l Lymphoma: A Narrative Review

@nl

type

label

Pruritus Reduction with System ...... l Lymphoma: A Narrative Review

@ast

Pruritus Reduction with System ...... l Lymphoma: A Narrative Review

@en

Pruritus Reduction with System ...... l Lymphoma: A Narrative Review

@nl

prefLabel

Pruritus Reduction with System ...... l Lymphoma: A Narrative Review

@ast

Pruritus Reduction with System ...... l Lymphoma: A Narrative Review

@en

Pruritus Reduction with System ...... l Lymphoma: A Narrative Review

@nl

P1433

Q28075343-502A98F0-AB0E-4E02-86B4-AC7F5C0D1A39

P1476

Q28075343-B7F5B42A-D757-4A4B-95A7-91CC95C421D4

P2093

Q28075343-3497F557-17B1-4510-8C5E-14940A9A1B38

Q28075343-45B37B97-9E69-466D-8880-81F3FFBE6318

Q28075343-6D438120-20BD-45CB-ABE6-148D2C2B776F

Q28075343-834EE36D-2E83-4F4F-9259-A17122A58D85

P2507

Q28075343-28525907-D38D-42A6-B194-1C92D9E2F9AB

P2860

Q28075343-0664E9D8-225F-44FF-B165-84BE6FA9DB9A

Q28075343-072B0433-1009-45B1-85AC-256E44F2BE50

Q28075343-0DFA6564-CFE0-41F5-A266-F38C25FD3C28

Q28075343-16F1D401-1329-4335-9443-6011C72AC7BF

Q28075343-1C2D34B1-0B07-4EDA-8E01-36E47D02138F

Q28075343-1C4853C4-B5DF-4E1C-8B2E-A89C5B497BEE

Q28075343-1DB424AA-2044-49E6-8E4F-7B8C70900091

Q28075343-20906276-E5D4-4123-B82C-0DB8966F7C2A

Q28075343-242B962F-3C80-447C-AC7B-778C10B31D80

Q28075343-2BB5AE9D-9162-4058-B550-F5F3E905FEAB

P2888

Q28075343-6588E9BE-A3B7-45F4-BE46-93AE04C08C14

P304

Q28075343-0EF4BF8B-3015-451D-BB52-348C2976EF17

P31

Q28075343-1A6BEFAE-44FE-4A5D-97C2-5BBADE365667

P3181

Q28075343-1E988CBC-F1AA-45F6-813F-81590E61BCE2

P356

Q28075343-CC2DA1FB-D7A6-4726-9D2C-EFDF1F7F9986

P407

Q28075343-6F3414A5-EEED-4ADA-BE87-B03425CB3C6B

P433

Q28075343-AF4DFE07-6FE8-4A3C-967C-4CD5108E08DB

P478

Q28075343-40A563EE-A213-4DAD-AFAC-AC379D6FB1E4

P577

Q28075343-81E2F49D-EC69-4173-AB96-46CC9274095F

P6179

Q28075343-79F2F0A5-AB4F-4811-A926-09C51BE1B85A

P698

Q28075343-5E80DC61-DBD1-4A82-91A0-C2502899EB16

P932

Q28075343-0E64DAB7-E382-431E-91F9-F8B65673DC38

P3181

P356

S13555-016-0143-4

P1433

Dermatology and therapy

P1476

Pruritus Reduction with System ...... l Lymphoma: A Narrative Review

@en

P2093

Halle Field

http://www.w3.org/2001/XMLSchema#string

Henry K. Wong

http://www.w3.org/2001/XMLSchema#string

Ling Gao

http://www.w3.org/2001/XMLSchema#string

Pooja Motwani

http://www.w3.org/2001/XMLSchema#string

P2507

Erratum to: Pruritus Reduction with Systemic Anti-lymphoma Treatments in Patients with Cutaneous T Cell Lymphoma: A Narrative Review.

P2860

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

IL-31: a new link between T cells and pruritus in atopic skin inflammation

Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions

Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance

Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data

Chemical phylogenetics of histone deacetylases.

Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey.

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.

P2888

s13555-016-0143-4

P304

579-595

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3693701

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S13555-016-0143-4

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1009782336

http://www.w3.org/2001/XMLSchema#string

P698

27590615

http://www.w3.org/2001/XMLSchema#string

P932

5120632

http://www.w3.org/2001/XMLSchema#string